The sBLA is supported by data from Studies A and B of phase 3 LIBERTY-CUPID trial which included patients with CSU who were inadequately controlled on standard-of-care H1 antihistamines.
— DRUG MONOGRAPHS BY SUBSECTION —
News and Features
18.9 percent of children and 25.7 percent of adults had seasonal allergy; 10.8 and 7.3 percent had eczema in 2021
Odactra is an allergen extract indicated as immunotherapy for the treatment of HDM-induced allergic rhinitis.
Association seen between infant exposure to acid-suppressive medications and increased asthma risk in offspring
The Food and Drug Administration (FDA) has approved Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp; Aimmune Therapeutics) for the treatment of peanut allergy.